Certara stock has given a MAJOR bull signal recently with the Resurrection CrossWhen the 50 day moving average crosses above the 200 day moving average, it is called a Resurrection Cross. Conversely, when the 50 day moving average crosses below the 200 day mov... in the stock. In this article we will look at that pattern and also the fundamental reasons that could be driving the stock higher.
What Does Certara Do?
Certara Inc. provides customers with technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It provides patients with medications by transforming drug discovery and development through the use of biosimulation software, technology, and services. In order to help its clients’ new drugs get approved and reach the market, the company also offers related technology-enabled services.
The company’s technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company also provides software, such as platforms for mechanistic biosimulation, empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, platform for authoring and managing regulatory submissions, and platform for market access communication. The business provides services to academic and governmental institutions, as well as biopharmaceutical companies.
Certara Stock Chart
Certara stock confirmed a Resurrection Cross on February 16, 2023. The stock is in a technical strong uptrend.
Analysts predict that Certara, a biotech stock, will report 2022 net incomeThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... of $69.7 million when it releases its earnings results next month. A $13.3 million loss was recorded in 2021 after the company went public in December 2020. According to FactSet, the stock has an average price target that suggests a potential upside of 11%, and almost 80% of analysts who follow Certara rate the company as overweight or a buy.
Certara Stock Price Target Raised at Barclays
On January 24, 2023, Barclays analyst Luke Sergott maintained an Overweight rating on the stock while increasing the price target for Certara to $20 from $17. In terms of traditional tools versus bioprocessing names, the analyst predicts 2023 will probably be a tale of two cities. According to the firm’s research note to investors, the year is likely in favor of conservative management teams with a track record of beating estimates.
Certara Acquires AI Company Vyasa
On January 4, 2023, Certara announced it has acquired Vyasa Analytics. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The company said, “The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence capabilities to its end-to-end platform. Formed in 2017, Vyasa software provides a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Vyasa’s leading product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text, and images, offers AI capabilities to support decisions in all phases of drug development.”